Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_assertion type Assertion NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_head.
- NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_assertion description "[In contrast to tissue testing, which is a one-time event, monitoring the circulating levels of the HER2/neu ECD in patients with breast cancer provides a real-time assessment of the HER2/neu status and provides important information for managing the therapy of patients with MBC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_provenance.
- NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_assertion evidence source_evidence_literature NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_provenance.
- NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_assertion SIO_000772 15245613 NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_provenance.
- NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_assertion wasDerivedFrom befree-2016 NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_provenance.
- NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_assertion wasGeneratedBy ECO_0000203 NP451439.RAzgLH1hV0Snn4Fm4s8gVoO_z0VjHlvOAQ5dpN9wGYdTY130_provenance.